<span style="margin-left: 0em;">chemotherapy</span> <span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">durvalumab based treatment</span> <span style="margin-left: 3em;">durvalumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">nivolumab based treatment</span> <span style="margin-left: 3em;">nivolumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">pembrolizumab based treatment</span> <span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 1em;">Immune checkpoint association</span> <span style="margin-left: 2em;">durvalumab plus tremelimumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (4) progression or deaths (PFS) (4) objective responses (ORR) (4) DOR (3) DCR (2) deaths (OS) (extension) (1) PFS (extension) (1) objective responses (ORR) (extension) (1) TRAE (any grade) (5) TRAE leading to death (grade 5) (5) TRAE leading to discontinuation (any grade) (4) TRAE (grade 3-4) (3) AE (any grade) (2) SAE (any grade) (2) AE leading to treatment discontinuation (any grade) (2) AE (grade 3-4) (2) AE leading to death (grade 5) (2) STRAE (any grade) (1) TRAE leading to discontinuation (grade 3-4) (1) Alopecia TRAE (grade 3-4) (4) Pruritus TRAE (grade 3-4) (4) Leucopenia TRAE (grade 3-4) (4) Diarrhoea TRAE (grade 3-4) (4) Fatigue TRAE (grade 3-4) (4) Increased ALT TRAE (grade 3-4) (4) Stomatitis TRAE (grade 3-4) (4) Mucosal inflammation TRAE (grade 3-4) (4) Hypothyroidism TRAE (grade 3-4) (4) Neutropenia TRAE (grade 3-4) (4) Nausea TRAE (grade 3-4) (4) Thrombocytopenia TRAE (grade 3-4) (4) Anaemia TRAE (grade 3-4) (4) Decreased appetite TRAE (grade 3-4) (4) Asthenia TRAE (grade 3-4) (4) Rash TRAE (grade 3-4) (3) Peripheral neuropathy TRAE (grade 3-4) (3) Dermatitis acneiform TRAE (grade 3-4) (2) Infusion-related reactions TRAE (grade 3-4) (3) Pneumonitis TRAE (grade 3-4) (3) Adrenal insufficiency TRAE (grade 3-4) (2) Increase AST TRAE (grade 3-4) (2) Hepatitis TRAE (grade 3-4) (2) Colitis TRAE (grade 3-4) (2) Skin and subcutaneous tissue disorders TRAE (grade 3-4) (2) Gastrointestinal disorders TRAE (grade 3-4) (2) Endocrine disorders TRAE (grade 3-4) (2) Maculopapular rash TRAE (grade 3-4) (2) Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) (2) Renal and urinary disorders TRAE (grade 3-4) (2) Hypersensitivity TRAE (grade 3-4) (2) Weight decreased TRAE (grade 3-4) (2) Pyrexia TRAE (grade 3-4) (2) Hyperthyroidism TRAE (grade 3-4) (2) Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) (2) Skin exfoliation TRAE (grade 3-4) (2) Acute kidney injury TRAE (grade 3-4) (2) Hepatobiliary disorders TRAE (grade 3-4) (2) Pruritic rash TRAE (grade 3-4) (1) Vomiting TRAE (grade 3-4) (1) Constipation TRAE (grade 3-4) (1) Severe skin reaction TRAE (grade 3-4) (1) Paraesthesia TRAE (grade 3-4) (1) Cough TRAE (grade 3-4) (1) Peripheral oedema TRAE (grade 3-4) (1) Myalgia TRAE (grade 3-4) (1) Headache TRAE (grade 3-4) (1) Epistaxis TRAE (grade 3-4) (1) Hypophysitis TRAE (grade 3-4) (1) Increased lipase level TRAE (grade 3-4) (1) Dyspepsia TRAE (grade 3-4) (1) Hypertension TRAE (grade 3-4) (1) Chills TRAE (grade 3-4) (1) Thyroiditis TRAE (grade 3-4) (1) Urticaria TRAE (grade 3-4) (1) Arthralgia TRAE (grade 3-4) (1) Eczema TRAE (grade 3-4) (1) Dry skin TRAE (grade 3-4) (1) Blood creatinine increased TRAE (grade 3-4) (1) Pruritus generalised TRAE (grade 3-4) (1) Dyspnoea TRAE (grade 3-4) (1) Nervous system disorders TRAE (grade 3-4) (1) Eye disorders TRAE (grade 3-4) (1) Erythema TRAE (grade 3-4) (1) Febrile neutropenia TRAE (grade 3-4) (1) Pancytopenia TRAE (grade 3-4) (1) Blood and lymphatic system disorders TRAE (grade 3-4) (1) Cardiac disorders TRAE (grade 3-4) (1) Gastritis TRAE (grade 3-4) (1) General disorders and administration site conditions TRAE (grade 3-4) (1) Sepsis TRAE (grade 3-4) (1) Metabolism and nutrition disorders TRAE (grade 3-4) (1) Musculoskeletal and connective tissue disorders TRAE (grade 3-4) (1) Stevens-Johnson syndrome TRAE (grade 3-4) (1) Vascular disorders TRAE (grade 3-4) (1) Guillain-Barré syndrome TRAE (grade 3-4) (1) Rash AE (grade 3-4) (1) Back pain AE (grade 3-4) (1) Dizziness AE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
1 CheckMate 141, 2016 1 KEYNOTE-040 (all population), 2018 1 EAGLE (D vs ICC), 2019 1 EAGLE (DT vs ICC), 2019 durvalumab alone vs. durvalumab plus tremelimumab
0.85 [0.64; 1.12] 0.85 [0.64;1.12]durvalumab alone vs. durvalumab plus tremelimumab
0.85 [0.64; 1.12] durvalumab alone vs. nivolumab alone
1.26 [0.86; 1.83] 1.26 [0.86;1.83]durvalumab alone vs. nivolumab alone
1.26 [0.86; 1.83] durvalumab alone vs. pembrolizumab alone
1.10 [0.82; 1.47] 1.10 [0.82;1.47]durvalumab alone vs. pembrolizumab alone
1.10 [0.82; 1.47] durvalumab alone vs. Standard of Care (SoC)
0.88 [0.72; 1.08] 0.88 [0.72;1.08]durvalumab alone vs. Standard of Care (SoC)
0.88 [0.72; 1.08] durvalumab plus tremelimumab vs. durvalumab alone
1.18 [0.89; 1.57] 1.18 [0.89;1.57]durvalumab plus tremelimumab vs. durvalumab alone
1.18 [0.89; 1.57] durvalumab plus tremelimumab vs. nivolumab alone
nivolumab alone better
1.49 [1.02; 2.16] 1.49 [1.02;2.16]durvalumab plus tremelimumab vs. nivolumab alone
nivolumab alone better
1.49 [1.02; 2.16] durvalumab plus tremelimumab vs. pembrolizumab alone
1.30 [0.98; 1.73] 1.30 [0.98;1.73]durvalumab plus tremelimumab vs. pembrolizumab alone
1.30 [0.98; 1.73] durvalumab plus tremelimumab vs. Standard of Care (SoC)
1.04 [0.85; 1.27] 1.04 [0.85;1.27]durvalumab plus tremelimumab vs. Standard of Care (SoC)
1.04 [0.85; 1.27] nivolumab alone vs. durvalumab alone
0.80 [0.55; 1.16] 0.80 [0.55;1.16]nivolumab alone vs. durvalumab alone
0.80 [0.55; 1.16] nivolumab alone vs. durvalumab plus tremelimumab
nivolumab alone better
0.67 [0.46; 0.98] 0.67 [0.46;0.98]nivolumab alone vs. durvalumab plus tremelimumab
nivolumab alone better
0.67 [0.46; 0.98] nivolumab alone vs. pembrolizumab alone
0.87 [0.60; 1.28] 0.87 [0.60;1.28]nivolumab alone vs. pembrolizumab alone
0.87 [0.60; 1.28] nivolumab alone vs. Standard of Care (SoC)
nivolumab alone better
0.70 [0.51; 0.96] 0.70 [0.51;0.96]nivolumab alone vs. Standard of Care (SoC)
nivolumab alone better
0.70 [0.51; 0.96] pembrolizumab alone vs. durvalumab alone
0.91 [0.68; 1.21] 0.91 [0.68;1.21]pembrolizumab alone vs. durvalumab alone
0.91 [0.68; 1.21] pembrolizumab alone vs. durvalumab plus tremelimumab
0.77 [0.58; 1.02] 0.77 [0.58;1.02]pembrolizumab alone vs. durvalumab plus tremelimumab
0.77 [0.58; 1.02] pembrolizumab alone vs. nivolumab alone
1.14 [0.78; 1.67] 1.14 [0.78;1.67]pembrolizumab alone vs. nivolumab alone
1.14 [0.78; 1.67] pembrolizumab alone vs. Standard of Care (SoC)
pembrolizumab alone better
0.80 [0.65; 0.98] 0.80 [0.65;0.98]pembrolizumab alone vs. Standard of Care (SoC)
pembrolizumab alone better
0.80 [0.65; 0.98] Standard of Care (SoC) vs. durvalumab alone
1.14 [0.93; 1.39] 1.14 [0.93;1.39]Standard of Care (SoC) vs. durvalumab alone
1.14 [0.93; 1.39] Standard of Care (SoC) vs. durvalumab plus tremelimumab
0.96 [0.79; 1.17] 0.96 [0.79;1.17]Standard of Care (SoC) vs. durvalumab plus tremelimumab
0.96 [0.79; 1.17] Standard of Care (SoC) vs. nivolumab alone
nivolumab alone better
1.43 [1.04; 1.96] 1.43 [1.04;1.96]Standard of Care (SoC) vs. nivolumab alone
nivolumab alone better
1.43 [1.04; 1.96] Standard of Care (SoC) vs. pembrolizumab alone
pembrolizumab alone better
1.25 [1.02; 1.53] 1.25 [1.02;1.53]Standard of Care (SoC) vs. pembrolizumab alone
pembrolizumab alone better
1.25 [1.02; 1.53] Standard of Care (SoC) nivolumab alone pembrolizumab alone durvalumab alone durvalumab plus tremelimumab direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C Standard of Care (SoC) nivolumab alone pembrolizumab alone durvalumab alone durvalumab plus tremelimumab Standard of Care (SoC) --- 1.43 1.04; 1.961.25 1.02; 1.531.14 0.93; 1.390.96 0.79; 1.17nivolumab alone 0.70 0.51; 0.96--- 0.87 0.60; 1.280.80 0.55; 1.160.67 0.46; 0.98pembrolizumab alone 0.80 0.65; 0.981.14 0.78; 1.67--- 0.91 0.68; 1.210.77 0.58; 1.02durvalumab alone 0.88 0.72; 1.081.26 0.86; 1.831.10 0.82; 1.47--- 0.85 0.64; 1.12durvalumab plus tremelimumab 1.04 0.85; 1.271.49 1.02; 2.161.30 0.98; 1.731.18 0.89; 1.57---
pathologies: 101
- treatments: 634,861
result logic